Loading clinical trials...
Loading clinical trials...
An Open Label Study to Evaluate the Effect on Bone Mineral Density, and the Safety, of Quarterly Intravenous Bonviva in Patients With Post-menopausal Osteoporosis.
This single arm study will assess the efficacy and safety of quarterly intravenous Bonviva in women with post-menopausal osteoporosis. All patients will receive Bonviva 3mg i.v. every 3 months. The anticipated time on study treatment is 3-12 months, and the target sample size is 100 individuals.
Age
0 - 80 years
Sex
FEMALE
Healthy Volunteers
No
Chai Yi, Taiwan
Changhua, Taiwan
Kaohsiung City, Taiwan
Kaohsiung City, Taiwan
Kaohsiung City, Taiwan
Taichung, Taiwan
Taichung, Taiwan
Taichung, Taiwan
Tainan, Taiwan
Tainan, Taiwan
Start Date
June 1, 2007
Primary Completion Date
December 1, 2010
Completion Date
December 1, 2010
Last Updated
November 2, 2016
ibandronate [Bonviva/Boniva]
DRUG
Lead Sponsor
Hoffmann-La Roche
NCT05010590
NCT07329543
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05060380